Sarcoidosis
Sarcoidosis is an intricate and multi-system inflammatory ailment whose origins are still debated, but its manifestations are undoubtedly severe. It’s pathophysiology is even more astonishing. The company guarantees the presence of an efficient team of highly skilled professionals harnessing state-of-the-art technology which, in turn, aids the research processes involved in creating pioneering precise therapeutics.
Introduction to Sarcoidosis
Sarcoidosis is a systematic disorder sarcoidosis stemming from an undetermined cough as combination of lesions with satellite non caseating granulomas. Apart from the lungs, it also affects the lymph nodes, eyes and skin, and eventually results in irreversible changes to organs and a deterioration in the species' standard of living. The disease is globally distributed with its prevalence s between 2.3 and 11 cases per 100,000 people.
Fig.1 Current and investigational therapeutics for sarcoidosis based on pathogenesis. (Gerke A. K., 2020)Pathogenesis of Sarcoidosis
Sarcoidosis develops when the body's immune system suddenly and aggressively targets unfamiliar substances or stimuli. These structures then form characteristics clusters called granulomas. Sarcoid pus is a surprise form of bizarre effusions commonly made up of aggregates of colloidal cells. These strange macrophages often provoke autoimmune reactions and, when ingested, irritate and provoke inflammation in the damaged organ.
Biomarkers for Sarcoidosis Diagnostics
Advances in technology such as transcriptomics are helpful in identifying useful biomarkers for the sarcoidosis diagnosis, as well as controlling document therapy development. There are some biomarkers that are related to sarcoidosis.
- Serum Angiotensin-Converting Enzyme
- Lysozyme
- Neopterin
- YKL40
- sCD163
- CC Chemokine Ligand 18
- Serum Amyloid A
- Chitotriosidase
Therapeutics of Sarcoidosis
Small Molecule Drugs Therapy
For cyclophosphamide resistant patients, immunosuppressors such as methotrexate or azathioprine are prescribed. Chloroquine and hydroxychloroquine have been used to treat skin manifestations of sarcoidosis with some success.
Monoclonal Antibodies Therapy
Newer therapies using monoclonal antibodies against TNF itself (infliximab, adalimumab, golimumab) and new strategies with targeted B cell therapy (rituximab) are considered to be new horizons for bettering the individuals' life.
Our Services
In the pursuit of researching rare disorders, our frontier is devoted to bringing scientific vigor to the examination of sarcoidosis. We are able to offer services ranging from mechanistic investigations through new therapy assessments, which encompass animal models, new therapeutic platform development, and the evaluative support for your studies on sarcoidosis.
Platforms of Sarcoidosis Therapy Development
Animal Models of Sarcoidosis
Chemically induced or genetically engineered animal models can assist you in the understanding of the pathophysiology of sarcoidosis and the development of novel therapeutics.
| Chemical-induced Models | ||
|---|---|---|
| Chemical-induced models cause the formation of granulomas using Th1-type immune response inducing Mycobacteria-specific antigens such as superoxide dismutase A (SodA), early secreted antigenic target 6-kD protein (ESAT-6), and catalase-peroxidase (KatG). Additionally, injecting an animal with P.acnes or multi-walled carbon nanotube (MWCNT) can encourage granuloma formation. | ||
| Optional Models |
|
|
|
|
|
|
||
| Genetically Engineered Models | ||
| Gene editing techniques allow modifying animal-specific genes like tuberous sclerosis complex 2 (Tsc2) genes, enabling these animals to exhibit systemic granuloma characteristics (on the lung, lymph nodes, liver, and skin). | ||
| Optional Models |
|
|
| Optional Species | Mice, Rats, Zebrafish, Rabbit, Non-Human Primates, Others | |
We can provide comprehensive services in sarcoidosis to help you with pharmacokinetics and drug safety evaluation. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Gerke, Alicia K. "Treatment of Sarcoidosis: A Multidisciplinary Approach." Frontiers in immunology 11 (2020): 545413.
- Kraaijvanger, Raisa et al. "Biomarkers in the Diagnosis and Prognosis of Sarcoidosis: Current Use and Future Prospects." Frontiers in immunology 11 (2020): 1443.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.